8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 29, 2026·SEC
Revelation Biosciences, Inc.(REVB)Earnings, Financials & Key Ratios
REVB•NASDAQ
$1.02
$633216 mkt cap·Price updated May 6, 2026
AboutRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$9M-13.8%
- Net Income-$9M+40.7%
- EPS (Diluted)-23.95+72.7%
- ROE-131.38%+50.4%
- Debt/Equity0.08
REVB Key Insights
Revelation Biosciences, Inc. (REVB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Profits declining 40.5% over 5 years
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
REVB Price & Volume
Revelation Biosciences, Inc. (REVB) stock price & volume — 10-year historical chart
Loading chart...
REVB Growth Metrics
Revelation Biosciences, Inc. (REVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM40.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.03%
Return on Capital
10 Years-935.37%
5 Years-994.11%
3 Years-164.07%
Last Year-126.93%
REVB Peer Comparison
Revelation Biosciences, Inc. (REVB) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 DYAI | 27.51M | 0.76 | -3.80 | 20.58% | -279.56% | -281.83% | 2.05 | |
 IBRX | 8.25B | 8.38 | -13.52 | 22.71% | -422.28% | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 |
Compare REVB vs Peers
Revelation Biosciences, Inc. (REVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
REVB Income Statement
Revelation Biosciences, Inc. (REVB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 69.17K | 40.01K | 25.05K | 27.92K | 27.06K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -69.17K▲ 0% | -40.01K▲ 42.2% | -25.05K▲ 37.4% | -27.92K▼ 11.5% | -27.06K▲ 3.1% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 42.16% | 37.39% | -11.47% | 3.1% |
| Operating Expenses | 3.64K | 3.8M | 11.95M | 10.86M | 8.66M | 7.98M | 9.07M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.64K | 1.23M | 5.04M | 5.49M | 4.51M | 4.43M | 5.01M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 0 | 2.56M | 6.91M | 5.38M | 4.15M | 3.55M | 4.06M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.64K▲ 0% | -3.8M▼ 104238.1% | -11.95M▼ 214.8% | -10.86M▲ 9.1% | -8.66M▲ 20.3% | -7.98M▲ 7.9% | -9.07M▼ 13.7% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -104238.07% | -214.83% | 9.09% | 20.32% | 7.87% | -13.74% |
| EBITDA | -3.64K | 0 | -11.93M | -10.84M | -8.63M | -7.95M | -9.04M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 100% | - | 9.17% | 20.37% | 7.93% | -13.8% |
| D&A (Non-Cash Add-back) | 0 | 3.8M | 16.78K | 25.05K | 25.05K | 27.92K | 27.06K |
| EBIT | -3.64K | -3.8M | -11.95M | -10.86M | -8.66M | -7.98M | -9.07M |
| Net Interest Income | 0 | 10.91K | -41.76K | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 10.91K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 41.76K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 126 | -36.35K | 34.96K | 8.54M | -7.06M | 157.16K |
| Pretax Income | -3.64K▲ 0% | -3.8M▼ 104234.6% | -11.99M▼ 215.8% | -10.83M▲ 9.7% | -120.25K▲ 98.9% | -15.04M▼ 12405.6% | -8.91M▲ 40.7% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.64K▲ 0% | -1.63M▼ 44718.6% | -11.99M▼ 635.2% | -10.83M▲ 9.7% | -120.25K▲ 98.9% | -15.04M▼ 12405.6% | -8.91M▲ 40.7% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -44718.58% | -635.16% | 9.65% | 98.89% | -12405.64% | 40.73% |
| Net Income (Continuing) | -3.64K | -3.8M | -11.99M | -10.83M | -120.25K | -15.04M | -8.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.72▲ 0% | -9032.69▼ 134315.0% | -20400.00▼ 125.8% | -9643.37▲ 52.7% | -8.41▲ 99.9% | -87.68▼ 942.6% | -23.95▲ 72.7% |
| EPS Growth % | - | -134315.03% | -125.85% | 52.73% | 99.91% | -942.57% | 72.68% |
| EPS (Basic) | -6.72 | -9032.69 | -20400.00 | -9643.37 | -8.41 | -87.68 | -23.95 |
| Diluted Shares Outstanding | 542 | 181 | 588 | 1.12K | 14.29K | 171.51K | 620.8K |
| Basic Shares Outstanding | 542 | 181 | 588 | 1.12K | 14.29K | 171.51K | 620.8K |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
REVB Balance Sheet
Revelation Biosciences, Inc. (REVB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 0 | 4.62M | 1.91M | 5.41M | 12.15M | 6.57M | 10.81M |
| Cash & Short-Term Investments | 0 | 4.49M | 1.27M | 5.25M | 11.99M | 6.5M | 10.7M |
| Cash Only | 0 | 4.49M | 1.27M | 5.25M | 11.99M | 6.5M | 10.7M |
| Short-Term Investments | 0 | 525.29K | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 148.73K | 160.3K | 100.61K | 49.5K | 33.95K |
| Total Non-Current Assets | 22.67K | 0 | 130.14K | 90.13K | 65.08K | 56.33K | 771.3K |
| Property, Plant & Equipment | 0 | 0 | 130.14K | 90.13K | 65.08K | 56.33K | 740.36K |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 73.51M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 22.67K | -73.51M | 0 | 0 | 0 | 0 | 30.94K |
| Total Assets | 22.67K▲ 0% | 4.62M▲ 20280.2% | 2.04M▼ 55.8% | 5.5M▲ 169.5% | 12.21M▲ 121.9% | 6.62M▼ 45.8% | 11.58M▲ 74.9% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 20280.22% | -55.8% | 169.48% | 121.91% | -45.78% | 74.91% |
| Total Current Liabilities | 26.31K | 3.43M | 2.14M | 4.45M | 5.56M | 1.91M | 2M |
| Accounts Payable | 0 | 865.9K | 596.26K | 554.21K | 1.36M | 783.62K | 577.5K |
| Days Payables Outstanding | - | - | 3.15K | 5.06K | 19.82K | 10.24K | 7.79K |
| Short-Term Debt | 0 | 0 | 16.75K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 26.31K | 2.22M | -16.75K | 2.91M | 3.44M | 2.25K | 0 |
| Current Ratio | - | 1.35x | 0.89x | 1.22x | 2.18x | 3.43x | 5.41x |
| Quick Ratio | - | 1.35x | 0.89x | 1.22x | 2.18x | 3.43x | 5.41x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 2.91M | 0 | 0 | 0 | 0 | 723.77K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 723.77K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 2.91M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 26.31K | 1.21M | 2.14M | 4.45M | 5.56M | 1.91M | 2.72M |
| Total Debt | 0 | 0 | 16.75K | 0 | 0 | 0 | 746.78K |
| Net Debt | 0 | -4.49M | -1.26M | -5.25M | -11.99M | -6.5M | -9.95M |
| Debt / Equity | - | - | - | - | - | - | 0.08x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -286.18x | - | - | - | - |
| Total Equity | -3.64K▲ 0% | 3.41M▲ 93877.5% | -99.47K▼ 102.9% | 1.05M▲ 1158.1% | 6.65M▲ 531.6% | 4.71M▼ 29.2% | 8.86M▲ 88.2% |
| Equity Growth % | - | 93877.46% | -102.92% | 1158.06% | 531.64% | -29.17% | 88.2% |
| Book Value per Share | -6.72 | 18899.95 | -169.29 | 937.18 | 465.20 | 27.45 | 14.27 |
| Total Shareholders' Equity | -3.64K | 3.41M | -99.47K | 1.05M | 6.65M | 4.71M | 8.86M |
| Common Stock | 0 | 2.29K | 282 | 77 | 265 | 522 | 1.58K |
| Retained Earnings | -3.64K | -2.53M | -14.52M | -25.35M | -25.47M | -40.51M | -49.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
REVB Cash Flow Statement
Revelation Biosciences, Inc. (REVB) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -215.07K | -11.09M | -11.22M | -7.29M | -18.32M | -8.27M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | - | -5056.63% | -1.16% | 35.06% | -151.45% | 54.86% |
| Net Income | -3.64K | -1.63M | -11.99M | -10.83M | -120.25K | -15.04M | -8.91M |
| Depreciation & Amortization | 0 | 0 | 16.78K | 25.05K | 25.05K | 27.92K | 27.06K |
| Stock-Based Compensation | 0 | 43.85K | 470.88K | 301.12K | 155.72K | 168.85K | 595.37K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 1.45M | 52.38K | 14.96K | -8.33M | -56.44K | 27.68K |
| Working Capital Changes | 3.64K | -80.5K | 356.22K | -730.97K | 982.13K | -3.42M | -6.04K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -269.64K | -666.04K | 749.66K | -576.28K | -206.12K |
| Cash from Investing | 0 | -74.04M | -131.96K | 0 | 0 | -19.17K | 0 |
| Capital Expenditures | 0 | 0 | -131.96K | 0 | 0 | -19.17K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -525.29K | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 74.26M | 8M | 15.2M | 14.03M | 12.85M | 12.47M |
| Debt Issued (Net) | 0 | 15K | 0 | -796.88K | 0 | 0 | 0 |
| Equity Issued (Net) | -10K | 74.25M | 8M | 4.46M | 14.02M | 12.85M | 12.47M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 10K | 0 | 0 | 11.54M | 34 | 0 | 0 |
| Net Change in Cash | 0▲ 0% | 11.73K▲ 0% | -3.22M▼ 27521.8% | 3.98M▲ 223.6% | 6.74M▲ 69.4% | -5.49M▼ 181.5% | 4.2M▲ 176.5% |
| Free Cash Flow | 0▲ 0% | -215.07K▲ 0% | -11.22M▼ 5118.1% | -11.22M▲ 0.0% | -7.29M▲ 35.1% | -18.34M▼ 151.7% | -8.27M▲ 54.9% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | - | -5118.09% | 0.03% | 35.06% | -151.71% | 54.91% |
| FCF per Share | - | -1191.46 | -19099.53 | -9990.56 | -509.89 | -106.94 | -13.32 |
| FCF Conversion (FCF/Net Income) | - | 0.13x | 0.93x | 1.04x | 60.59x | 1.22x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
REVB Key Ratios
Revelation Biosciences, Inc. (REVB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -95.69% | -723.81% | -2272.77% | -3.12% | -264.85% | -131.38% |
| Debt / Equity | - | - | - | - | - | - | 0.08x |
| Interest Coverage | - | - | -286.18x | - | - | - | - |
| FCF Conversion | - | 0.13x | 0.93x | 1.04x | 60.59x | 1.22x | 0.93x |
REVB SEC Filings & Documents
Revelation Biosciences, Inc. (REVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
REVB Frequently Asked Questions
Revelation Biosciences, Inc. (REVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Revelation Biosciences, Inc. (REVB) grew revenue by 0.0% over the past year. Growth has been modest.
Revelation Biosciences, Inc. (REVB) reported a net loss of $8.9M for fiscal year 2025.
Dividend & Returns
Revelation Biosciences, Inc. (REVB) has a return on equity (ROE) of -131.4%. Negative ROE indicates the company is unprofitable.
Revelation Biosciences, Inc. (REVB) had negative free cash flow of $8.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More REVB
Revelation Biosciences, Inc. (REVB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates